Infinitus Launches Studio, the First Healthcare-Specific No-Code AI Agent Builder

TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting

West Reports First-Quarter 2026 Results

Superdrug désigne Hanshow comme partenaire pour les étiquettes électroniques en rayon pour faire avancer la prochaine phase de numérisation du commerce de détail dans les secteurs de la santé et de la beauté

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

SkylineDx to Present Data on Precision Molecular Diagnostics Advances in Cutaneous Squamous Cell Carcinoma at 22nd EADO Congress

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia

2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

DUAL-PATHWAY BLOCKADE THERAPY OFFERS HOPE FOR RARE, HARD-TO-TREAT GYNAECOLOGICAL CLEAR CELL CANCERS

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

NEDHSA to Host Lincoln Parish NED Talk Road Tour in Grambling, LA: Focusing on Underage Drinking/Substance Abuse Workshop and Interactive Alcohol Simulation Experience

2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety

What drives multimillion-dollar medical claims? Sun Life report shows secondary health conditions, hospital stays and specialty drugs among key factors

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prestige Consumer Healthcare Inc. - PBH

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

AANP TAKES LEGAL ACTION TO PROTECT FUTURE NURSE PRACTITIONERS AND PATIENT ACCESS TO CARE

Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting

Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting

Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

Athlete Playmakers Group Announces Continued National Expansion with Multiple New Airport Openings Planned for 2026

David P. King elected to Illumina's Board of Directors

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

Enliven Therapeutics to Present at Upcoming Investor Conferences